Empagliflozin receives Fast Track designation in US for use to improve outcomes following a heart attack

The EMPACT-MI study is currently underway, investigating the effect of empagliflozin on all-cause mortality and hospitalisation for heart failure in adults with and without type 2 diabetes who have had an acute myocardial infarction and no history of chronic heart failure.


Biospace Inc.